Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Update

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 17,650,000 shares, an increase of 11.4% from the December 31st total of 15,840,000 shares. Approximately 12.7% of the company’s stock are sold short. Based on an average daily trading volume, of 6,670,000 shares, the short-interest ratio is currently 2.6 days.

Bionano Genomics Stock Up 2.1 %

Bionano Genomics stock traded up $0.11 during midday trading on Monday, reaching $5.30. The company’s stock had a trading volume of 233,420 shares, compared to its average volume of 352,757. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99. Bionano Genomics has a 52-week low of $4.75 and a 52-week high of $81.00. The stock has a market capitalization of $10.35 million, a P/E ratio of -0.04 and a beta of 2.22. The stock’s 50-day simple moving average is $12.61 and its 200-day simple moving average is $20.61.

Institutional Trading of Bionano Genomics

A number of institutional investors have recently made changes to their positions in BNGO. Geode Capital Management LLC raised its holdings in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after purchasing an additional 283,639 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Bionano Genomics during the 3rd quarter worth $46,000. Finally, Carret Asset Management LLC lifted its position in shares of Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after acquiring an additional 40,055 shares during the period. 11.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.